Background
==========

Neuroblastoma is the most common and deadly extracranial solid childhood tumor, exhibiting remarkable variation in clinical presentation ranging from localized to highly metastatic disease. Despite multimodal therapies, survival rates for aggressive neuroblastomas are still disappointingly low. One possible approach to development of more efficient and less toxic therapies is to gain insight into the signaling pathways that are deregulated in neuroblastoma and to use this information in the design of molecular therapies. However, at present only two genes, namely *MYCN*and *PHOX2B*, have been directly linked to neuroblastoma development, although their exact role in oncogenesis is still unclear \[[@B1],[@B2]\].

It is hoped that genome-wide gene expression studies will provide insights into the genes and molecular pathways that govern neuroblastoma pathogenesis. Thus far, no clear or consistent candidate genes or pathways have emerged from these analyses \[[@B3]-[@B5]\] (see Additional data file 3 for more references). Both for currently available expression data and forthcoming datasets, we anticipate that transcriptome information on the cells of origin of neuroblastoma (sympathetic nervous system progenitors) will be of crucial importance and could provide significant power on data mining strategies.

The sympathetic nervous system is composed of sympathetic chain and truncus ganglia, paraganglia, and the adrenal gland. Ganglion cells (neuroblasts during development) are the major cell type of chain and truncus ganglia, and extra-adrenal chromaffin cells form the paraganglia, whereas the adrenal gland is composed of adrenal chromaffin cells and, at least during development, sympathetic neuroblasts. The fate of the neuroblasts in the developing human adrenal gland is not clear; some or all may involute or mature as solitary intra-adrenal neurons \[[@B6]\]. Evidence for the cellular origin of neuroblastoma is based on their occurrence in the adrenal gland or along the spinal cord in association with sympathetic ganglia, and on their neuroblastic phenotype that indicates that the tumor cells are derived from immature sympathetic nervous system cells of the ganglionic lineage \[[@B7]\]. Indeed, cells of adrenal neuroblastomas have neuroblastic morphology and do not express the adrenal chromaffin marker *PNMT*, but they share phenotypic characteristics with the immature sympathetic neuroblasts present as nests of cells in the developing adrenal gland. However, a small subset of neuroblastomas also contains cells with extra-adrenal chromaffin characteristics.

In the present study we isolated and performed expression profiling of the human adrenal neuroblasts as they form monocellular structures during early fetal stages, which can be easily microdissected. In parallel, favorable and unfavorable neuroblastoma tumors were profiled on the same platform. Finally, our dataset was integrated in a meta-analytical data mining approach.

Results
=======

Characterization, isolation, and gene expression profiling of fetal adrenal neuroblasts
---------------------------------------------------------------------------------------

Prescreening of hematoxylin-eosin cryosections from 11 fetal adrenal glands demonstrated that large neuroblast clusters of more than 100 cells were predominantly found in adrenal glands at 19 and 20 weeks\' gestational age (Figure [1a](#F1){ref-type="fig"}). To verify that these cell clusters indeed represent neuroblasts and to estimate the degree of intermingled chromaffin cells, cryosections were stained for the neuronal and chromaffin marker TH (tyrosine hydroxylase), the chromaffin marker CHGA (chromogranin A; which also has low expression in neuroblasts), and the neuronal markers BCL2 (B-cell CLL/lymphoma 2) and HNK1 (carbohydrate epitope) \[[@B8]\]. As shown in Figure [1](#F1){ref-type="fig"}, the clusters of neuroblastic cells stained positive for all markers and, in particular, these cells were positive for BCL2 and HNK1. The majority of chromaffin cells, identified by their strong CHGA and TH expression, were found to be scattered throughout the adrenal cortex (these cells coalesce and form large islands of chromaffin cells later during development), whereas a few cells were located in or adjacent to the neuroblast clusters.

Neuroblast clusters and adjacent cortical cells (used as controls) were isolated using laser capture microdissection from stained cryosections from three different fetal adrenal glands (glands 1, 2 and 3, which were of gestational ages 20, 19 and 19 weeks, respectively) (Figure [2](#F2){ref-type="fig"}) and immediately lysed in RNA extraction buffer. In order to obtain a sufficient amount of good quality neuroblast RNA for oligonucleotide chip analyses, we applied a previously validated protocol for tissue sectioning, staining, and microdissection \[[@B9]\] (Additional data file 1(a)). By pooling different isolates of the same adrenal gland, between 2.5 and 15 ng total RNA could be obtained for each of the three neuroblast samples (Additional data file 1(b)). After two-round amplification and labeling of three neuroblast, three cortex, and 18 neuroblastoma RNA samples, hybridization was performed on HG-U133A Affymetrix oligonucleotide chips. Real-time polymerase chain reaction analysis of selected genes showed that there was no RNA amplification bias in the chip data (Additional data file 1(c)).

Validation of the expression profile of fetal adrenal neuroblasts and cortex cells
----------------------------------------------------------------------------------

The expression profiles of the neuroblast and cortex samples were compared using the rank product nonparametric method, which is particularly suited for extracting significantly differentially expressed genes in a limited number of samples \[[@B10]\]. Two lists of 156 and 86 unique genes were established with significantly higher expression in neuroblast and adrenal cortex cells, respectively (multiple testing corrected *P*\< 0.01; Additional data file 2). Gene Ontology (GO) analysis identified those classes of genes that are significantly over-represented in the cell specific gene lists (*P*\< 0.01; Table [1](#T1){ref-type="table"}). As expected, the neuroblast gene list is enriched for genes that are involved in catecholamine metabolism, neurogenesis and other neural processes, whereas cortex cells specifically express genes involved in steroid and cholesterol metabolism.

To further test the validity of the neuroblast gene expression profile, we evaluated the expression of known neuronal and chromaffin markers that were previously studied in human fetal sections \[[@B8]\]. High expression (among the 10% most abundant genes) of neuronal markers (*BCL2*, *GAP43*, and *NPY*) together with chromaffin (and to a lesser extent neuronal) markers (*CHGA*, *CHGB*, *DBH*, *DDC*and *TH*) and an adrenal chromaffin marker (*PNMT*) in the microdissected cell clusters is in keeping with our observation that the neuroblast isolates are pure, with only rare intermingled chromaffin cells (Figure [1](#F1){ref-type="fig"}).

Gene set enrichment analysis \[[@B11]\] based on expression of the 156 neuroblast-specific genes in 79 human tissues \[[@B12]\] was performed in order to explore whether the microdissected neuroblasts indeed have neural characteristics. The neuroblasts exhibit a significant overlap in expression with various nervous system tissues (*P*\< 0.05; fetal brain, prefrontal cortex, brain amygdale, whole brain, occipital lobe, and hypothalamus), further demonstrating that the proper cells were microdissected.

Similarity between the expression profiles of neuroblast and neuroblastoma further supports the \'cell of origin\' concept
--------------------------------------------------------------------------------------------------------------------------

Although multiple lines of evidence indicate that neuroblastoma originates from immature sympathetic neuroblasts, the mRNA expression repertoire of these neuroblasts and neuroblastomas have not yet been compared. Before our analysis, we assumed that, in addition to differences resulting from oncogenic transformation, both cell populations would exhibit many cell type specific similarities.

Three data mining strategies were employed to investigate this hypothesis. First, an unbiased multidimensional scaling of all genes on the chip showed that the neuroblasts cluster close to the neuroblastoma tumors and that both groups cluster far away from the fetal adrenal cortex cells (Figure [3a](#F3){ref-type="fig"}). Second, we extended our dataset with publicly available expression profiles (measured on the same platform) from 79 normal tissues \[[@B12]\]and three neural stem cell cultures \[[@B13]\]. Based on the genes that are differentially expressed between the neuroblasts and cortex samples (156 and 86 genes, respectively), multidimensional scaling showed again that the neuroblastoma tumors cluster close to the neuroblasts and further away from the other normal tissues. Interestingly, the neural stem cells also cluster close to the neuroblastomas and neuroblasts (Figure [3b](#F3){ref-type="fig"}). These findings further support the notion that adrenal neuroblasts are indeed of neuronal origin with possible neuronal stem cell features, and the observed considerable similarities to neuroblastomas in terms of expression give further strength to the \'cell of origin\' hypothesis for neuroblastoma development.

Third, we looked for similarities in mRNA expression between neuroblast and neuroblastoma by cataloging their expression repertoire. We defined a reasonable cut-off to determine whether a gene is expressed or not in a given sample (the mean percentage of present calls for the various chips; Additional data file 1(d)). As such, the 36% most highly expressed probe IDs in the cortex, neuroblast and neuroblastoma cells, were selected and compared in a Venn diagram. This analysis clearly shows that neuroblasts have more expressed genes in common with neuroblastoma than with the cortex cells (432 versus 292; Figure [4a](#F4){ref-type="fig"}). GO analysis on the common 432 genes revealed an expected over-representation of neurogenesis genes (*P*\< 0.01; data not shown). Next, we zoomed in on neurogenesis and transcription factor ontology classes by performing a similar Venn diagram for these gene sets, assuming their putative importance in neuroblastoma development. Interestingly, the similarities between neuroblast and neuroblastoma are even more pronounced for these two GO classes (Figure [4b, c](#F4){ref-type="fig"}).

Identifying genes and pathways putatively implicated in neuroblastoma pathogenesis through differential expression analysis of normal neuroblasts and neuroblastomas
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the final and most challenging part of our data mining approach, we aimed to identify genes that are under-expressed or over-expressed in neuroblastomas compared with neuroblasts, because these genes and the pathways that they govern might be involved in neuroblastoma development or represent markers for the stage of developmental arrest of neuroblastomas. Rank product analysis (multiple testing corrected *P*\< 0.01) yielded a list of 71 genes that were more highly expressed in neuroblasts and 565 genes that were more highly expressed in neuroblastomas (Additional data file 2).

A first crucial step in our data mining strategy to identify genes that are putatively involved in neuroblastoma was a meta-analysis of our generated gene lists in published neuroblastoma microarray data. We used the Neuroblastoma Gene Server (NBGS) which was developed in-house (see Additional data file 3 for detailed information) to compare the neuroblast-specific and neuroblastoma-specific gene lists with genes that have been reported as differentially expressed in 25 previous gene expression profiling studies conducted in neuroblastoma (Additional data file 3). We found that as many as 17 of the 71 genes (24%) that are over-expressed in neuroblasts relative to neuroblastomas were reported in the NBGS, mainly annotated as genes that are more highly expressed in maturing, differentiating, or localized neuroblastomas. Likewise, 102 out of the 565 genes (18%) that were over-expressed in neuroblastoma were previously identified in other gene expression studies on neuroblastoma. The high overlap of our gene lists with published gene lists demonstrates the validity of our lists, which were subsequently further explored in chromosomal mapping, GO, and pathway analysis.

Positional expression mapping of candidate oncogenes and tumor suppressor genes
-------------------------------------------------------------------------------

Chromosome 17q gain is the most frequent genetic aberration in neuroblastoma and is assumed to play a crucial role in its pathogenesis through a dosage effect of one or more genes. This critical region still comprises 25 megabases (Mb) \[[@B14]\], precluding straightforward candidate gene identification. Here we apply an alternative, intuitive strategy to pinpoint putative critical dosage sensitive loci. Using positional gene enrichment analysis (De Preter and coworkers, unpublished data) \[[@B15]\], we sought chromosomal loci that are significantly over-represented in the list of genes that are over-expressed in neuroblastoma relative to their normal cells of origin (Figure [5](#F5){ref-type="fig"}). We found two peaks on chromosome 17q, with high significance for a locus on 17q21.32-q22 that coincides with the consistently gained segment just distal from the most distal breakpoint in a series of high-resolution copy number profiles (Vandesompele and coworkers, unpublished data).

Apart from over-expressed genes, we also sought positional tumor suppressor genes by mapping under-expressed genes (relative to normal neuroblasts). The following positional candidates could be identified, located within or very close to the known shortest regions of overlap in neuroblastoma: *CASP9*on 1p36; *CACNA2D3*, *TDGF1*and *NKTR*on 3p21-p22 (SRO (shortest region of overlap) from \[[@B16]\]); *IGSF4*, *APOA1*, *MLL*and *RDX*on 11q23 \[[@B17]-[@B19]\]; and *MEG3*and *DLK1*on 14q32 \[[@B20]\].

GO analysis
-----------

To examine gene expression differences between neuroblasts and neuroblastomas from a different perspective, we mapped the neuroblast-specific and neuroblastoma-specific gene lists to the biologic process GO classification (Table [2](#T2){ref-type="table"}). This revealed that the neuroblasts express significantly (*P*\< 0.01) more genes that are involved in steroid and catecholamine metabolism compared with neuroblastomas. Neuroblastomas are characterized by an over-representation of genes that are involved in immune response, cell growth, and cell cycle. The immune response gene signature may be due to infiltrating immune cells, whereas the over-representation of cell growth and cell cycle genes in neuroblastomas is in perfect concordance with the hyperproliferative character of tumors.

We then specifically looked at genes belonging to GO terms neurogenesis, transcription factor activity, and apoptosis; these three processes can be assumed to play an important role in neuroblastoma pathogenesis (Table [3](#T3){ref-type="table"}). This analysis identified the following interesting genes from the neuroblast-specific and neuroblastoma-specific gene lists: transcription factors involved in neurogenesis *TFAP2B*(6p12.3; more highly expressed in neuroblasts); *ASCL1*(12q23.2), *SIX3*(2p21) and *STAT3*(17q21.2; more highly expressed in neuroblastoma); and *APOE*(19q13.31) and *INHBA*(7p14.1; more highly expressed in neuroblastoma), which are involved in both apoptosis and neurogenesis.

Differential expression analysis of favorable and unfavorable neuroblastomas
----------------------------------------------------------------------------

Thus far, most published microarray studies on neuroblastomas mainly compared favorable with unfavorable neuroblastomas in order to identify prognostic markers or pathways that are involved in these clearly different neuroblastoma tumor types. In order to add value to such an analysis, we contrasted similar differentially expressed gene lists with the normal neuroblast expression profile (Additional data file 2). In a first step, we compared the differentially expressed genes between these two tumor types with published prognostic gene lists. We found that 25 of the 194 genes on our list were previously reported, including the well established markers *MYCN*, *NTRK1*, and *CD44*(see NBGS analysis in Additional data file 3). This overlap demonstrates the validity of the selected neuroblastoma panel and their expression profile. Subsequently, we sought the corresponding gene expression levels of the differentially expressed genes in the normal counterpart cells, aiming to select neuroblastoma candidate genes. Of the 95 genes that are more highly expressed in favorable tumors (versus unfavorable ones), 37 also have significant differential expression (either higher or lower) compared with neuroblasts, whereas 41 out of the 101 genes that are more highly expressed in unfavorable tumors exhibit differential expression compared with the neuroblasts (Table [4](#T4){ref-type="table"}).

From this analysis, a few putative positional tumor suppressor candidates emerge: *CDC42*on 1p36, *CACNA2D3*on 3p21, and *DLK1*on 14q. The latter two genes are of particular interest because they are highly expressed in neuroblasts and favorable neuroblastomas, and their expression is significantly lower in unfavorable neuroblastomas. Among the genes that are more highly expressed in unfavorable neuroblastomas than in favorable ones and neuroblasts, the proven oncogenic transcription factor *MYCN*emerges (and putative downstream genes *KIFAP3*, *OPHN1, RGS7*, *ODC1*, *TOP2A*, *TWIST1*and *TYMS*, according to NBGS*)*, as do several other genes that have been identified or studied within the context of neuroblastomas such as *ALK*and *PRAME*, and positional candidates on 17q including *BIRC5*, *RNU2*and *TOP2A*.

Expression of neurogenesis markers in neuroblasts and developmental origin of neuroblastoma
-------------------------------------------------------------------------------------------

Although this was not the primary aim of the present work, the neuroblast expression profile provides a unique resource for the investigation of gene expression in human sympatho-adrenal progenitors. In a first attempt, we made an inventory of the genes that belong to the neurogenesis GO class, or that have been described to play a role in neural crest formation and migration, or that have proneural activity (Additional data file 4). This analysis showed that human fetal neuroblasts of 19 weeks\' gestational age expressed 174 of the 359 genes in the neurogenesis GO class, and 26 of 89 proneural genes and genes involved in neural crest formation/migration.

To obtain possible clues on the developmental origin of neuroblastoma we compared the expression profiles of the neuroblastoma tumors with those of normal neuroblasts and neural stem cell cultures. Intersectional Venn diagram analysis of expressed genes shows that neuroblastomas have many genes in common with neuroblasts, as already shown above (Figure [6](#F6){ref-type="fig"}). Interestingly, when compared with neuroblasts, the neuroblastomas have more genes in common with the self-renewing neural stem cells (535 versus 145), among others the neurogenesis genes *ASCL1*, *GSS*, *STAT3*, *UTP11L*, *ENAH*, *APBB2*, *CDK5RAP2*, and *LARGE*.

Discussion
==========

Comparison of the mRNA expression repertoire of cancer with that of their normal counterpart cells is a commonly applied strategy to elucidate the development and pathophysiology of the cancer type under study. For pediatric neuroblastoma, fetal adrenal sympathetic neuroblasts are assumed to be the cells of origin, but these cells are virtually absent after birth and thus not readily accessible for analysis \[[@B8]\]. In this study we were able, for the first time, to determine the expression profile of microdissected islets of fetal sympathetic neuroblasts, providing an important landmark for comparative expression analysis. In parallel, adjacent cortex cells and carefully selected representative neuroblastoma tumors were profiled for data mining purposes. Our main goals were to provide support for the cell of origin hypothesis of neuroblastoma, and to obtain preliminary insights into the disrupted cellular circuitry that is involved in neuroblastoma pathogenesis.

Quality assessment and biologic validation of the established neuroblast expression profile demonstrated that the proper cells were isolated and that their expression profiles are trustworthy. Next, we assessed the cell of origin hypothesis for neuroblastomas. To this end, the transcriptional profile of the neuroblasts was thoroughly compared with those of neuroblastoma tumors and normal tissues. These analyses confirmed that neuroblast and neuroblastoma cells indeed present with highly similar expression profiles. These exploratory findings provide, for the first time, molecular support for the cell of origin hypothesis. Also, they reinforce our assumption that the neuroblast gene expression profile constitutes a valid tool for further data mining of neuroblastoma gene expression patterns.

Following initial data validation and assessment of the cell of origin hypothesis, we performed a series of data mining analyses aimed at identifying genes and pathways that may be involved in neuroblastoma oncogenesis and tumor biology. In a first step, the neuroblastoma tumor expression profile was compared with that of the neuroblasts, yielding 71 genes with higher expression in neuroblasts and 565 genes with increased expression in neuroblastoma. We subjected these gene lists to a novel meta-analytical approach that allowed comparison with 25 published neuroblastoma gene lists and facilitated the detection of genes identified in at least one other microarray study. Furthermore, we performed GO analysis and we used a new approach to positional mapping of the differentially expressed genes. In a second step, following analysis of combined tumors, we sought genes differentially expressed in carefully selected representative cases of favorable and unfavorable neuroblastomas and further analyzed the expression of these genes in neuroblasts. This approach yielded 37 and 41 genes, respectively.

When combining the data from the above analyses, it was apparent that many of the genes previously reported in the context of neuroblastoma had been identified, thus underscoring the validity of our data mining approach. These included *MYCN*, *MYCN*co-amplified genes such as *DDX1*, known *MYCN*target genes such as *ODC1*and *MCM7*, and prognostic markers (*MYCN*, *NTRK1*, and *CD44*), as well as various other genes such as *ASCL1*, *ALK*, *BCL2*, *BIRC5*, *DLK1*, *NME1*, *NME2*and *NTRK3*that have previously been mentioned or studied within the context of neuroblastoma. For some genes only circumstantial evidence for a role in neuroblastoma is present (*WSB1*, *CDC42*, *PLAGL1*, *PRAME*and *TGFBR3*); that we identified these genes in the present study warrants further investigations into their possible role in neuroblastoma development. Finally, several genes, for which no evidence of involvement in neuroblastoma development has yet been obtained, emerged for the first time from our analyses. These include *STAT3*, *IGSF4*and *CACNA2D3*, and they should also be studied in further detail to determine their possible role in neuroblastoma pathogenesis.

Although the present study is just a first step in a new strategy of data mining of neuroblastoma gene expression profiles, we nevertheless obtained new information that is particularly interesting for the 17q region. Gain of distal 17q is not only the most frequent chromosomal alteration in high stage neuroblastoma but it is also the strongest independent adverse prognostic genetic factor \[[@B21],[@B22]\]. However, no functional evidence has been provided for a specific role of 17q genes in neuroblastoma development. A major obstacle is the difficulty in refining the critical region for 17q gain that, as a consequence, has remained very large, hampering selection of functional candidates. Based on recent high-resolution array-CGH (comparative genome hybridization) profiling of 17q breakpoints leading to gain for distal 17q, we have proposed the hypothesis that the critical region for 17q gain is located within a 5 Mb segment on 17q21.32-q22, immediately distal to the most distal breakpoint (Vandesompele and coworkers, unpublished data).

To substantiate this hypothesis, we performed positional gene enrichment analysis on chromosome 17 for the genes that are more highly expressed in neuroblastoma compared to neuroblast. Interestingly, this yielded a highly significant enrichment for two loci on the long arm of chromosome 17, including the above mentioned region, further demonstrating the high likelihood of the presence of a neuroblastoma dosage sensitive gene. A total of 11 differentially expressed genes are contained within this 17q21.3 segment, including *NME1*and *NME2*. The role of the latter two genes in cancer is controversial, but once again these genes emerge from a neuroblastoma study. Among the genes that are more highly expressed in neuroblastoma, another interesting candidate was found to be located just outside the enriched 17q21.3 segment but within the same chromosome band, namely *STAT3*. This gene encodes an oncogenic transcription factor that plays a central role in the janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, promoting growth and survival of tumor cells, inducing tumor angiogenesis, and suppressing antitumor immune responses. Of particular interest is that *STAT3*is also implicated in neurogenesis. Given their documented role in cancer, STAT proteins have been shown to be promising molecular targets for novel cancer therapies, including small molecule inhibitors of STAT signaling. The finding of increased *STAT3*expression might also be of relevance in the light of the observed *ALK*over-expression in this and previous studies \[[@B23],[@B24]\], because ALKis known to activate STAT3 by phosphorylation \[[@B25]\]. Suppression of activated ALK in neuroblastoma cells by RNA interference was shown to lead to rapid apoptosis \[[@B26]\].

Positional mapping of the genes that are expressed to a lesser degree in neuroblastomas than in neuroblasts yielded some remarkable positional tumor suppressor candidate genes. Among others, these include *CASP9*and *CDC42*(1p36), which have already been studied in neuroblastoma \[[@B27],[@B28]\]; *CACNA2D3*(3p21-p22), which was recently proposed as a tumor suppressor gene in lung cancer \[[@B29]\]; *IGSF4*(11q23), which is a known tumor suppressor gene in several cancers; and *DLK1*(14q). All of these genes have been mapped within or near to previously defined shortest regions of overlap for deletions in neuroblastoma and should therefore be considered for further functional studies.

Yet another interesting candidate neuroblastoma suppressor gene is *WSB1*. This gene was found in four published neuroblastoma microarray studies to be more highly expressed in favorable neuroblastomas. Moreover, *WSB1*was very recently shown to be associated with prognosis \[[@B30]\]. Recent evidence indicated that WSB1 (WD repeat and SOCS box-containing 1) is part of an E3 ubiquitin ligase and that it exhibits similarity with an interchangeable F-box protein β-TrCP1 that is implicated in nuclear factor-κB, Wnt/Wingless, and hedgehog signaling pathways \[[@B31],[@B32]\]. Together with other unpublished data on the possible implications of the Wnt pathway in neuroblastomas, we speculate that reduced ubiquitination of β-catenin caused by low levels of *WSB1*expression in unfavorable neuroblastomas could lead to upregulation of several genes that are involved in cell proliferation \[[@B33]\].

Finally, *PLAGL1*was identified as a candidate neuroblastoma tumor suppressor gene in the present study. This gene regulates apoptosis and cell cycle arrest and plays a role in the control of cell fate during neurogenesis \[[@B34]\]. *PLAGL1*is localized on chromosome 6q24-q25, a region that is frequently deleted or epigenetically modified in many solid tumors \[[@B35]\], including neuroblastoma (unpublished data).

The dataset presented will also be of future value for the study of sympathetic nervous system development and the developmental stage from which neuroblastoma originates. Ideally, more neuroblast samples from different gestation times should be collected in order to gain broader insight. The present neuroblast collections offer a glimpse into this developmental process, as illustrated by the expression of *ASCL1*and *DLK1*. *ASCL1*is a known early neurogenesis marker \[[@B36]\], which was confirmed by the observed expression in the immature self-renewing neural stem cells and the absence in the more mature neuroblasts. The significantly higher expression in part of the unfavorable neuroblastomas compared with the neuroblasts might denote an earlier stage of differentiation arrest or reflect a process of de-differentiation of the unfavorable neuroblastoma cells. *DLK1*, on the other hand, is expressed to a lesser degree in the unfavorable neuroblastoma than in the favorable tumors and the neuroblast (in concordance with observations reported by Hsiao and coworkers \[[@B37]\]). Later in neural development, DLK1 (delta-like 1 homolog) downregulates ASCL1 (achaete-scute complex-like 1) through NOTCH (notch homolog), further inducing neuronal differentiation \[[@B38]\]. Hence, these expression differences indicate a different time point of developmental arrest for favorable and unfavorable neuroblastoma, as was previously suggested.

Conclusion
==========

The inclusion of normal neuroblasts in gene expression analysis of malignant neuroblastomas was shown to add significant power to the identification of candidate neuroblastoma genes. Inclusion of larger sets of neuroblastoma tumors with well characterized genomic alterations and positional mapping of the genes in critically involved genomic regions in neuroblastomas will be crucial for tracing back the molecular basis of neuroblastoma.

Materials and methods
=====================

Fetal and tumor material
------------------------

Ethical approval was obtained for the collection of fetal adrenal glands from fetuses aborted for clinical reasons (Ethics committee Erasme Hospital, Brussels, Belgium; approval no.: OM021). The induced abortion was performed by prostaglandin instillation to the patient. The adrenals were removed during necropsy and snap-frozen in liquid nitrogen within 3 hours after delivery. Neuroblastoma tumors were collected in the Center for Medical Genetics (Ghent, Belgium; *n*= 12), in the National Center for Medical Genetics (Dublin, Ireland; *n*= 1), and in the University Children\'s Hospital of Essen (Essen, Germany; *n*= 5). For this study, we preferentially selected tumors that were localized in the adrenal gland (11/18). Based on INSS stage (international neuroblastoma staging system), *MYCN*status, ploidy and age at diagnosis, and for some cases pathologic rapports, samples were divided into favorable or unfavorable neuroblastoma (Table [5](#T5){ref-type="table"}).

Hematoxylin and eosin staining, immunohistochemistry, and laser capture microdissection
---------------------------------------------------------------------------------------

Fetal adrenal glands were embedded in Tissue-Tek OCT compound (Sakura, Torrance, CA, USA). Immunohistochemical staining was performed as described previously \[[@B8]\]. For microdissection, cryosections were first stained with hematoxylin and eosin, and mounted in order to scan for neuroblast clusters. When neuroblast clusters were found, stained but unmounted cryosections were prepared for laser capture microdissection. Embedding, sectioning, staining, and laser capture microdissection of neuroblast clusters and surrounding cortex cells was performed as described previously \[[@B9]\].

RNA isolation and quality assessment
------------------------------------

Microdissected cells were collected in RNA extraction buffer, followed by RNA extraction and DNase treatment on column (Qiagen, Venlo, Netherlands). RNA of the tumor samples was extracted using the RNeasy Mini kit (Qiagen), in accordance with the manufacturer\'s instructions. Four of the neuroblastoma tumor pieces were first mixed with Lysing Matrix D microbeads (Qbiogene, Illkirch, France) and 700 μl RTL buffer (Qiagen), and homogenized using FastPrep FP220 (Qbiogene). A fraction of the RNA was used for cDNA synthesis after DNase treatment (described by Vandesompele and coworkers \[[@B39]\]). RNA quality was measured with the RNA Nano or Pico LabChip kit (Agilent, Diegem, Belgium) using 1 μl of the RNA isolates.

Oligonucleotide chip analysis and data mining
---------------------------------------------

For each of the three fetal adrenal glands, the different neuroblast RNA isolates were pooled, amplified using a two-round labeling protocol, and hybridized to HG-U133A oligonucleotide chips (Affymetrix, Santa Clara, CA, USA), containing 18,400 transcripts including 14,500 well characterized human genes (protocol described previously \[[@B40]\]). The same amplification protocol was applied to RNA of three cortex samples and approximately 100 ng RNA of 18 neuroblastoma tumors. The homogeneity of the subgroups (neuroblast, cortex, favorable and unfavorable neuroblastoma) allowed us to use a limited number of samples for expression profiling. Several technical parameters demonstrate that the hybridization was of good quality (Additional data file 1(d)).

We obtained the raw data from the Genomics Institute of the Novartis Foundation compendium of normal tissues consisting of 79 normal tissues assayed in duplicate using the Affymetrix HG-U133A array \[[@B12]\]. Raw HG-U133A Affymetrix array data from three neural stem cells were kindly provided by Wright and coworkers \[[@B13]\].

CEL files were loaded in the R-Bioconductor (BioC) software and normalized with the Robust Multi Chip Average (RMA) method \[[@B41]\]. Identification of differentially expressed genes for pairwise comparisons were performed using the RankProd R-package, which is based on the Rank Product principle \[[@B10]\]. We used the GoHyperG function from the BioC project to find over-represented biologic process GO categories from the gene lists using hypergeometric test for significance. KEGG pathway analysis was performed with the Webgestalt web interface using hypergeometric test for significance \[[@B42]\].

Meta-analyses of published neuroblastoma microarray data were performed with the NBGS (see Additional data fiile 3 for detailed information).

Positional gene enrichment analysis was performed with in-house developed R-Bioconductor script PGE (De Preter and coworkers, unpublished data) \[[@B15]\]. PGE scans the entire genome using a moving window with a user-defined width (5 Mb) and step size (1 Mb). In each window, the -10log(p) of the Fisher Exact Test is calculated. This test was used to investigate whether there is an association between the gene list and a particular chromosomal region (the window under investigation). As such, it will identify regions that contain more (or less) genes in the gene list than expected by chance. The (known) unequal distribution of the genes along the chromosomes is taken into account, because the number of genes from the list that are located in the region is compared with the total number of genes in that particular region. Correction for multiple testing is performed using the false discovery rate method of Benjamini and Hochberg \[[@B43]\], using the R-multtest package.

Expression microarray data were submitted to ArrayExpress \[[@B44]\], accession number E-MEXP-669.

Additional data files
=====================

The following additional data are available with the online version of this paper. Additional data file [1](#S1){ref-type="supplementary-material"} includes documents on RNA quality and quantity measures, validation of Affymetrix chip results, and Affymetrix chip quality parameters \[[@B39],[@B45]-[@B49]\]. Additional data file [2](#S2){ref-type="supplementary-material"} lists genes that are differentially expressed in neuroblast versus cortex samples, in neuroblast versus favorable (F) and/or unfavorable (UF) neuroblastoma, and in favorable versus unfavorable neuroblastoma (identified using Rank Product algorithm). Additional data file [3](#S3){ref-type="supplementary-material"} provides results of NBGS analysis of the genes that are differentially expressed between neuroblasts and (favorable and/or unfavorable) neuroblastomas (gene lists in Additional data file 1). Additional data file [4](#S4){ref-type="supplementary-material"} lists the genes of GO class neurogenesis and proneural genes that are expressed in neuroblast samples (\> 36th percentile) \[[@B50]-[@B54]\].
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Figures and Tables
==================

![Identification of sympathetic neuroblasts and chromaffin cells in human fetal adrenal glands by immunohistochemical analysis. Sections of a human fetal (19 weeks) adrenal gland, adjacent to those used for laser capture retrieval of cells for mRNA extraction and gene expression profiling, were stained with **(a)**hematoxylin and eosin or antibodies directed against **(b,f)**TH, **(c,g)**CHGA, **(d,h)**BCL2, and **(e,i)**HNK1. Whereas the immunoreactivities of BCL2 and HNK1 are specific for neuroblasts, TH and CHGA expression is pronounced in chromaffin cells and weak in neuroblasts \[8\]. Stars indicate chromaffin cells (TH^+^, CHGA^+^, BCL2^-^, and HNK1^-^), either solitary or intermingled with neuroblasts. Panels a-e show a cluster of adrenal neuroblasts and panels f-i show cortical area within scattered chromaffin cells adjacent to the neuroblast cluster. Inserts in panels b-e (bars: 10 μm) correspond to the boxed areas in these panels (bars in panels a-i: 100 μm). BCL2, B-cell CLL/lymphoma 2; CHGA, chromogranin A; H&E, hematoxylin and eosin; HNK1, carbohydrate epitope; TH, tyrosine hydroxylase.](gb-2006-7-9-r84-1){#F1}

![Laser capture microdissection of neuroblast clusters. **(a)**Large cluster of neuroblasts in fetal adrenal glands at 19 weeks\' gestational age (mounted hematoxylin and eosin stained cryosections), **(b,c)**unmounted hematoxylin and eosin stained fetal adrenal cryosections with a neuroblast cluster before and after microdissection (sample 2), and **(d)**the microdissected neuroblast cluster.](gb-2006-7-9-r84-2){#F2}

![Multidimensional scaling of neuroblast, cortex, and neuroblastoma samples. **(a)**Multidimensional scaling of neuroblast, cortex, and neuroblastoma samples using all genes (Spearman correlation) and **(b)**multidimensional scaling of neuroblast, cortex, neuroblastoma, 79 normal tissue samples and other cancer samples (in duplo), and three neural stem cell cultures using the genes that are differentially expressed between fetal adrenal neuroblast and fetal adrenal cortex shows that the neuroblasts cluster very close to the neuroblastomas.](gb-2006-7-9-r84-3){#F3}

![Venn diagram analysis of the genes with detectable expression in neuroblastoma, neuroblast, and cortex samples. **(a)**All genes, **(b)**transcription factors (GO:0003700), and **(c)**neurogenesis genes (GO:0007399). The number of genes that are in common between neuroblast and neuroblastoma is higher than the number of genes that are in common between the neuroblasts and cortex samples (especially for the gene classes transcription and neurogenesis), indicating that neuroblastomas resemble neuroblasts. GO, Gene Ontology.](gb-2006-7-9-r84-4){#F4}

![Positional gene enrichment analysis of genes on chromosome 17. Positional gene enrichment analysis for the genes that are more highly expressed in neuroblastoma compared to normal neuroblasts identified two regions on 17q with significant over-representation (-^10^log *P*values; indicated in grey; the genes in these regions are printed in the boxes). The horizontal red line indicates the multiple testing corrected *P*value of 0.01, above which the positional gene enrichment value denotes significant over-representation. Vertical lines show the position of the genes on chromosome 17 from the gene list under investigation. The boxplot shows the gene density along the chromosome.](gb-2006-7-9-r84-5){#F5}

![Venn diagram analysis of genes with detectable expression in neuroblast, neuroblastoma, and neural stem cell lines. This analysis shows that neuroblasts have many genes in common with neuroblastoma, but it also demonstrates that neural stem cell lines have more genes in common with the neuroblastomas than with the normal neuroblasts.](gb-2006-7-9-r84-6){#F6}

###### 

GO analysis: neuroblast versus cortex samples

  GO                                                       *P*value   *n*   GO description
  -------------------------------------------------------- ---------- ----- ---------------------------------------
  More highly expressed in neuroblast compared to cortex                    
                                                                            
  GO:0007399                                               5.94E-09   20    Neurogenesis
  GO:0019226                                               1.12E-06   13    Transmission of nerve impulse
  GO:0007268                                               5.39E-06   12    Synaptic transmission
  GO:0001505                                               9.29E-05   5     Regulation of neurotransmitter levels
  GO:0007267                                               2.76E-04   16    Cell-cell signaling
  GO:0050877                                               3.17E-04   16    Neurophysiological process
  GO:0046879                                               3.47E-04   3     Hormone secretion
  GO:0006584                                               3.47E-04   3     Catecholamine metabolism
  GO:0018958                                               4.72E-04   3     Phenol metabolism
  GO:0048513                                               6.67E-04   22    Organ development
  GO:0006836                                               6.96E-04   4     Neurotransmitter transport
  GO:0009887                                               7.32E-04   21    Organogenesis
  GO:0007154                                               1.21E-03   46    Cell communication
  GO:0045055                                               1.25E-03   3     Regulated secretory pathway
  GO:0007269                                               1.25E-03   3     Neurotransmitter secretion
  GO:0046903                                               1.52E-03   8     Secretion
  GO:0030072                                               2.09E-03   2     Peptide hormone secretion
  GO:0030073                                               2.09E-03   2     Insulin secretion
  GO:0016079                                               2.09E-03   2     Synaptic vesicle exocytosis
  GO:0042423                                               2.09E-03   2     Catecholamine biosynthesis
  GO:0006887                                               2.24E-03   4     Exocytosis
  GO:0009653                                               2.77E-03   23    Morphogenesis
  GO:0007218                                               3.25E-03   4     Neuropeptide signaling pathway
  GO:0007275                                               3.26E-03   29    Development
  GO:0046883                                               5.70E-03   2     Regulation of hormone secretion
  GO:0030182                                               7.26E-03   2     Neuron differentiation
  GO:0048489                                               8.98E-03   2     Synaptic vesicle transport
                                                                            
  More highly expressed in cortex compared to neuroblast                    
                                                                            
  GO:0016126                                               4.18E-07   5     Sterol biosynthesis
  GO:0006694                                               9.28E-07   6     Steroid biosynthesis
  GO:0008202                                               4.32E-06   7     Steroid metabolism
  GO:0016125                                               2.93E-05   5     Sterol metabolism
  GO:0044255                                               6.74E-05   9     Cellular lipid metabolism
  GO:0006629                                               8.75E-05   10    Lipid metabolism
  GO:0008610                                               1.39E-04   6     Lipid biosynthesis
  GO:0006695                                               2.97E-04   3     Cholesterol biosynthesis
  GO:0006066                                               1.17E-03   6     Alcohol metabolism
  GO:0008203                                               4.69E-03   3     Cholesterol metabolism
  GO:0044242                                               4.97E-03   2     Cellular lipid catabolism
  GO:0006118                                               7.90E-03   5     Electron transport

Shown are over-represented GO classes (biological process) (with *P*\< 0.01 and at least two genes) in the list of genes that are more highly expressed in neuroblast than in cortex samples, and *vice versa*. GO, Gene Ontology.

###### 

GO analysis: normal neuroblasts compared to neuroblastomas

  GO                                                              *P*value   *n*   GO description
  --------------------------------------------------------------- ---------- ----- --------------------------------------------------------
  More highly expressed in neuroblast compared to neuroblastoma                    
                                                                                   
  GO:0008202                                                      1.33E-18   17    Steroid metabolism
  GO:0006694                                                      3.22E-15   12    Steroid biosynthesis
  GO:0044255                                                      2.13E-12   18    Cellular lipid metabolism
  GO:0008610                                                      8.54E-12   13    Lipid biosynthesis
  GO:0016125                                                      1.29E-11   10    Sterol metabolism
  GO:0006629                                                      1.50E-10   18    Lipid metabolism
  GO:0008203                                                      5.85E-09   8     Cholesterol metabolism
  GO:0008207                                                      1.37E-08   5     C21-steroid hormone metabolism
  GO:0006700                                                      1.37E-08   5     C21-steroid hormone biosynthesis
  GO:0006066                                                      1.55E-08   12    Alcohol metabolism
  GO:0042446                                                      9.26E-07   5     Hormone biosynthesis
  GO:0016126                                                      1.16E-06   5     Sterol biosynthesis
  GO:0042445                                                      9.57E-06   5     Hormone metabolism
  GO:0006118                                                      1.76E-05   9     Electron transport
  GO:0006869                                                      1.84E-05   5     Lipid transport
  GO:0009058                                                      4.62E-05   16    Biosynthesis
  GO:0006695                                                      5.39E-04   3     Cholesterol biosynthesis
  GO:0042423                                                      6.50E-04   2     Catecholamine biosynthesis
  GO:0006810                                                      2.29E-03   20    Transport
  GO:0006091                                                      2.32E-03   9     Generation of precursor metabolites and energy
  GO:0006584                                                      2.85E-03   2     Catecholamine metabolism
  GO:0051234                                                      2.88E-03   20    Establishment of localization
  GO:0051179                                                      3.04E-03   20    Localization
  GO:0018958                                                      3.46E-03   2     Phenol metabolism
  GO:0042401                                                      5.64E-03   2     Biogenic amine biosynthesis
  GO:0042398                                                      8.30E-03   2     Amino acid derivative biosynthesis
                                                                                   
  More highly expressed in neuroblastoma compared to neuroblast                    
                                                                                   
  GO:0019882                                                      4.54E-14   16    Antigen presentation
  GO:0030333                                                      2.51E-12   14    Antigen processing
  GO:0019884                                                      1.21E-08   8     Antigen presentation, exogenous antigen
  GO:0019886                                                      3.45E-08   8     Antigen processing, exogenous antigen via MHC class II
  GO:0019883                                                      4.23E-07   7     Antigen presentation, endogenous antigen
  GO:0006260                                                      2.07E-06   20    DNA replication
  GO:0006955                                                      2.45E-06   58    Immune response
  GO:0006952                                                      1.02E-05   60    Defense response
  GO:0019885                                                      1.03E-05   6     Antigen processing, endogenous antigen via MHC class I
  GO:0009607                                                      1.05E-05   66    Response to biotic stimulus
  GO:0006270                                                      9.25E-05   6     DNA replication initiation
  GO:0006259                                                      4.34E-04   35    DNA metabolism
  GO:0009596                                                      5.51E-04   4     Detection of pest, pathogen or parasite
  GO:0006261                                                      7.72E-04   10    DNA-dependent DNA replication
  GO:0050896                                                      1.03E-03   92    Response to stimulus
  GO:0006913                                                      1.42E-03   12    Nucleocytoplasmic transport
  GO:0007051                                                      1.84E-03   5     Spindle organization and biogenesis
  GO:0016070                                                      2.01E-03   25    RNA metabolism
  GO:0007052                                                      2.27E-03   4     Mitotic spindle organization and biogenesis
  GO:0009595                                                      2.27E-03   4     Detection of biotic stimulus
  GO:0007017                                                      2.67E-03   11    Microtubule-based process
  GO:0006658                                                      3.08E-03   2     Phosphatidylserine metabolism
  GO:0009613                                                      3.39E-03   34    Response to pest, pathogen or parasite
  GO:0006928                                                      3.94E-03   18    Cell motility
  GO:0040011                                                      3.94E-03   18    Locomotion
  GO:0043207                                                      4.72E-03   34    Response to external biotic stimulus
  GO:0007626                                                      5.10E-03   18    Locomotory behavior
  GO:0016043                                                      5.31E-03   46    Cell organization and biogenesis
  GO:0016049                                                      6.09E-03   12    Cell growth
  GO:0008361                                                      6.09E-03   12    Regulation of cell size
  GO:0042254                                                      6.39E-03   6     Ribosome biogenesis and assembly
  GO:0051169                                                      8.15E-03   10    Nuclear transport
  GO:0016071                                                      8.34E-03   16    Mrna metabolism
  GO:0043241                                                      8.91E-03   2     Protein complex disassembly
  GO:0031498                                                      8.91E-03   2     Chromatin disassembly
  GO:0006337                                                      8.91E-03   2     Nucleosome disassembly
  GO:0006104                                                      8.91E-03   2     Succinyl-coa metabolism
  GO:0007610                                                      9.44E-03   21    Behavior
  GO:0007049                                                      9.50E-03   39    Cell cycle

Shown are over-represented GO classes (biological process) (with *P*\< 0.01 and at least two genes) in the list of genes that are more highly expressed in normal neuroblasts than in neuroblastomas, and *vice versa*. GO, Gene Ontology.

###### 

Differentially expressed transcription factors, neurogenesis, and apoptosis genes

                                Transcription factor (GO:0003700)   Neurogenesis (GO:0007399)   Apoptosis (GO:0006915)                      
  ----------------------------- ----------------------------------- --------------------------- ------------------------ ----- ------------ -----
  Neuroblast \> neuroblastoma   *MLL*                               11q                         *APOE*                   19q   *APOE*       19q
                                *NR0B1*                             Xp                          *GREM1*                  15q   *PLAGL1*     6q
                                *RORA*                              15q                         *TFAP2B*                 6p    *SCARB1*     12q
                                *TFAP2B*                            6p                                                         *TDGF1*      3p
                                                                                                                                            
  Neuroblast \< neuroblastoma   *ASCL1\**                           12q                         *ALK*                    2p    *BCL2*       18q
                                *ATF3*                              1q                          *APBB2*                  4p    *BCLAF1*     6q
                                *CNOT7*                             8p                          *ASCL1*                  12q   *BIRC5*      17q
                                *CUTL2*                             12q                         *CDK5R1*                 17q   *CCL2*       17q
                                *ETV6*                              12p                         *FEZ1*                   11q   *CD2*        1p
                                *FOXC1*                             6p                          *GPI*                    19q   *CD74*       5q
                                *HCLS1*                             3q                          *INHBA*                  7p    *CIAPIN1*    16q
                                *IRF8*                              16q                         *LARGE*                  22q   *CYCS*       7p
                                *KLF10*                             8q                          *MBNL1*                  3q    *HTRA2*      2p
                                *MLX*                               17q                         *NEFH*                   22q   *IER3*       6p
                                *NFE2L1*                            17q                         *NTRK3*                  15q   *IGFBP3*     7p
                                *NFIB*                              9p                          *OLFM1*                  9q    *INHBA*      7p
                                *NME2*                              17q                         *PPT1*                   1p    *ITGB2*      21q
                                *RUNX1*                             21q                         *SERPINF1*               17p   *ITGB3BP*    1p
                                *SIX3*                              2p                          *SIX3*                   2p    *LGALS1*     22q
                                *STAT1*                             2q                          *SLIT1*                  10q   *LY86*       6p
                                *STAT3*                             17q                         *SOX11*                  2p    *OPA1*       3q
                                *TAF10*                             11p                         *STAT3*                  17q   *PRKCA*      17q
                                *TAF7*                              5q                          *TRAPPC4*                11q   *RNF130*     5q
                                *TFDP1*                             13q                                                        *STAT1*      2q
                                *TRIM22*                            11p                                                        *SULF1*      8q
                                *TSC22D1*                           13q                                                        *TNFRSF21*   6p
                                *ZNF91*                             19p                                                        *TUBB*       6p

Shown are differentially expressed genes in neuroblastoma versus neuroblasts that belong to GO terms transcription factor, neurogenesis, and/or apoptosis, with an indication of the chromosomal localization. GO, Gene Ontology.

###### 

Genes that are differentially expressed in favorable vs. unfavorable neuroblastoma

  Favorable NB \> unfavorable NB                             NBGS                                                       Favorable NB \< unfavorable NB   NBGS                                                             
  ---------------------------------------------------------- ---------------------------------------------------------- -------------------------------- ---------------------------------------------------------- ----- ----
                                                                                                                                                                                                                          
  neuroblast \< favorable NB                                 neuroblast \< favorable NB, neuroblast \< unfavorable NB                                                                                                     
                                                                                                                                                                                                                          
  *AKAP7*                                                    6q                                                         \-                               *FABP6*                                                    5q    \-
  *ARL7*                                                     2q                                                         \-                               *NEFL*                                                     8p    \-
  *ASPN*                                                     9q                                                         \-                               *NPY*                                                      7p    \-
                                                                                                                                                                                                                          
  *BCL2*                                                     18q                                                        1                                neuroblast \< unfavorable NB                                     
                                                                                                                                                                                                                          
  *C2orf23*                                                  2p                                                         \-                               *ALK*                                                      2p    \-
  *CALB1*                                                    8q                                                         \-                               *ASCL1*                                                    12q   1
  *CAMK2B*                                                   7p                                                         2                                *BIRC5*                                                    17q   3
  *CD24*                                                     6q                                                         \-                               *C22orf18*                                                 22q   \-
  *CDC42*                                                    1p                                                         1                                *C3*                                                       19p   \-
  *DDAH1*                                                    1p                                                         \-                               *CALCB*                                                    11p   \-
  *DNAPTP6*                                                  2q                                                         \-                               *CCNB1*                                                    5q    1
  *EPB41L3*                                                  18p                                                        1                                *CD74*                                                     5q    \-
  *FAM70A*                                                   Xq                                                         \-                               *CRH*                                                      8q    \-
  *KIFAP3*                                                   1q                                                         1                                *CSPG3*                                                    19p   \-
  *OPHN1*                                                    Xq                                                         \-                               *DNCI1*                                                    7q    \-
  *PDLIM5*                                                   4q                                                         \-                               *DTL*                                                      1     1
  *PPAN*                                                     19p                                                        \-                               *F12*                                                      5q    \-
  *PRKCB1*                                                   16p                                                        1                                *GFRA2*                                                    8p    \-
  *RGS7*                                                     1q                                                         2                                *IGHG3*                                                    14q   \-
  *RNF11*                                                    1p                                                         \-                               *IGHM*                                                     14q   \-
  *ST6GALNAC5*                                               1p                                                         \-                               *IGKC*                                                     2p    1
  *SV2C*                                                     5q                                                         \-                               *IGLC2*                                                    22q   \-
                                                                                                                                                                                                                          
  neuroblast \> favorable NB, neuroblast \> unfavorable NB   *LMO3*                                                     12p                              *1*                                                              
                                                                                                                                                                                                                          
  *CACNA2D3*                                                 3p                                                         \-                               *MGC27165*                                                 14q   \-
  *DLK1*                                                     14q                                                        2                                *MLF1IP*                                                   4q    1
  *HBG1*                                                     11p                                                        \-                               *MMP9*                                                     20q   1
  *HBG2*                                                     11p                                                        \-                               *MYCN*                                                     2p    9
                                                                                                                                                                                                                          
  neuroblast \> unfavorable NB                               *NEFH*                                                                                                                                                       
                                                                                                                                                                                                                          
  *ALDH3A2*                                                  17p                                                        1                                *ODC1*                                                     2p    3
  *DLC1*                                                     8p                                                         \-                               *OGDHL*                                                    10q   \-
  *EYA1*                                                     8q                                                         \-                               *P2RX5*                                                    17p   \-
  *GCH1*                                                     14q                                                        1                                *PRAME*                                                    22q   1
  *HBA2*                                                     16p                                                        \-                               *RPS4Y1*                                                   Yp    1
  *KIAA0960*                                                 7p                                                         1                                *SERPINF1*                                                 17p   \-
  *PTPRD*                                                    9p                                                         \-                               *TNFRSF10B*                                                8p    2
  *PTPRK*                                                    6q                                                         \-                               *TOP2A*                                                    17q   1
  *SLC18A1*                                                  8p                                                         \-                               *TWIST1*                                                   7p    1
  *TFAP2B*                                                   6p                                                         \-                               *TYMS*                                                     18p   \-
  *TLN2*                                                     15q                                                        1                                *XAGE1*                                                    Xp    \-
                                                                                                                                                                                                                          
                                                                                                                                                         neuroblast \> favorable NB, neuroblast \< unfavorable NB         
                                                                                                                                                                                                                          
                                                                                                                                                         *IGLJ3*                                                    22q   1
                                                                                                                                                                                                                          
                                                                                                                                                         neuroblast \> favorable NB                                       
                                                                                                                                                                                                                          
                                                                                                                                                         *RNU2*                                                     17q   \-
                                                                                                                                                                                                                          
                                                                                                                                                         neuroblast \> favorable NB, neuroblast \> unfavorable NB         
                                                                                                                                                                                                                          
                                                                                                                                                         *LOC492304*                                                11p   \-

Genes that are differentially expressed compared with neuroblasts among the differentially expressed genes in favorable neuroblastoma (NB) versus unfavorable neuroblastoma, with an indication of the number of neuroblastoma microarray studies in which these genes were found through NBGS analysis. NBGS, Neuroblastoma Gene Server.

###### 

Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study

  Sample number   Lab number   \% Tumor cells   Stage   *MYCN*amp   Ploidy   Adrenal localisation   Age         Dead/alive   Overall survival (months)   Type
  --------------- ------------ ---------------- ------- ----------- -------- ---------------------- ----------- ------------ --------------------------- -------------
  NB1             01T15        80               4S      No          Tri      Yes                    \< 1 year   Alive        61.4                        Favorable
  NB2             98T33        95               1       No          Tri      Yes                    \< 1 year   Alive        76.9                        Favorable
  NB3             96T82        90               1       No          Tri      Yes                    \< 1 year   Alive        115.5                       Favorable
  NB4             99T129       90               1       No          Tri      Yes                    \< 1 year   Alive        71.7                        Favorable
  NB5             01T28        90               4       Yes         Di       Yes                    \> 1 year   Dead         5.6                         Unfavorable
  NB6             03T304       100              3^a^    No          Di       Abdominal              \> 1 year   Alive        12.0                        Unfavorable
  NB7             03T236       90               4       No          ND       Yes                    \> 5 year   Dead         19.4                        Unfavorable
  NB8             00T54        70               1       No          Tri      Yes                    \< 1 year   Alive        62.6                        Favorable
  NB9             00T35        \> 95            4       Yes         Di       Yes                    \< 1 year   Dead         13.7                        Unfavorable
  NB10            99T125       80               3       No          Di       Yes                    \> 5 year   Alive        79.3                        Unfavorable
  NB11            92W145       70               4       No          ND       ND                     \> 5 year   Dead         19.5                        Unfavorable
  NB12            02T192       100              4       Yes         Di       Abdominal              \> 5 year   Dead         16.2                        Unfavorable
  NB13            D031         \> 95            4       No          Di       Abdominal              \> 1 year   Dead         64.8                        Unfavorable
  NB14            E002         \> 80            4       No          ND       Abdominal              \> 1 year   Alive        65.7                        Unfavorable
  NB15            E037         \> 80            4       No          ND       Abdominal              \> 1 year   Alive        45.3                        Unfavorable
  NB16            E044         \> 80            4       No          ND       Yes                    \< 1 year   Alive        37.0                        Unfavorable
  NB17            E121         \> 80            4       Yes         ND       Abdominal              \> 1 year   Dead         78.4                        Unfavorable
  NB18            04T121       60               3       Yes         Di       Yes                    \> 1 year   Dead         6                           Unfavorable

Based on stage, *MYCN*amplification, ploidy, and age at diagnosis, samples were subdivided into favorable or unfavorable type.

^a^Neuroblastoma or ganglioneuroblastoma. ND, not determined or unknown.
